TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06151912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Nausea and Vomiting scala
Description: The Nausea and Vomiting Intensity Scale will be used. Patients will be evaluated with this scale at 1, 6, 24 hours and one month. According to this scale, A total score of ≥50 at any time during the study period will be defined as clinically significant nausea and vomiting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Nausea and Vomiting scala
Description: The Nausea and Vomiting Intensity Scale will be used. Patients will be evaluated with this scale at 1, 6, 24 hours and one month. According to this scale, A total score of ≥50 at any time during the study period will be defined as clinically significant nausea and vomiting.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life
Description: The EuroQol Group (EQ-5D-5L) questionnaire will assess the quality of life in five domains (mobility, personal care, usual activities, pain and anxiety). A higher score indicates more excellent quality of life impairment. The survey will be administered to patients immediately before surgery and 24 hours and four weeks after surgery to establish baseline values.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of life
Description: The EuroQol Group (EQ-5D-5L) questionnaire will assess the quality of life in five domains (mobility, personal care, usual activities, pain and anxiety). A higher score indicates more excellent quality of life impairment. The survey will be administered to patients immediately before surgery and 24 hours and four weeks after surgery to establish baseline values.
Study: NCT05833048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: Participants will receive an ultrasound guided rectus sheath block with local anesthetic
Study: NCT06216379

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: Sensory processing skills and gross and fine motor development of preterm and term born children were evaluated.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: Sensory processing skills and gross and fine motor development of preterm and term born children were evaluated.
Study: NCT05692492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601
Description: 50mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1601
Description: 100mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05563519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: I-PRF with collagen
Description: The products will be applied to the sockets after tooth extractions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: The products will be applied to the sockets after tooth extractions
Study: NCT06461767

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation device
Description: Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation device
Description: Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation device
Description: Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation device
Description: Repetitive transcranial magnetic stimulation parameters:~stimulation site: left dorsolateral prefrontal cortex and left motor cortex intensity: 70% of resting motor threshold frequency: 15 Hz number of pulses: 30
Study: NCT06493344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applying additional weight
Description: Treadmill training with and without weight (15 minutes of 3 times/ per week for 16 weeks).
Study: NCT06182150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Indoor Cycling Exercise
Description: The 45-minute indoor cycling moderate-intensity cardiovascular exercise will take place once a week over four weeks. The group fitness-based class consists a 5-minute warm-up, a 35-minute conditioning segment, and a 5-minute cooldown.
Study: NCT06231420

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Encourage using pedometer
Description: Sarcopenic cirrhotic patient used pedometer recording actively with encourage by care provider or investigator

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pedometer
Description: pedometer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pedometer
Description: pedometer
Study: NCT06243731

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT04285242

Intervention type: OTHER
Intervention: Observational assessments
Description: Clinical assessments

Intervention type: OTHER
Intervention: Observational assessments
Description: Clinical assessments

Intervention type: OTHER
Intervention: Observational assessments
Description: Clinical assessments

Intervention type: OTHER
Intervention: Observational assessments
Description: Clinical assessments
Study: NCT05636189

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warming during induction of anesthesia
Description: Warming group patients are applied air-forced warming device (bair-hugger 43'C) with blanket (warm touch, COVIDIEN, full body blanket) during induction of anesthesia in the operation room.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prewarmed intravenous fluid administration
Description: Prewarmed intravenous fluid is connected.
Study: NCT05119218

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT06388304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE Online PAT Program
Description: Online program: behavioral intervention based on Positive Affect Training (PAT)
Study: NCT05040893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Interventions will include:~1. Education and self-management strategies, including the use of wearable activity and real-time heart rate monitors, to safely guide pacing and activity.~2. Breathing pattern education and retraining (including diaphragmatic, relaxed, and paced breathing exercises).~3. Return-to-activity exercise programming (e.g., postural, aerobic, and whole-body strengthening exercises).
Study: NCT05553483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pranayama plus acupoint stimulation by laser
Description: This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints and daily pranyama exercises (nearly every session will be one hour), the stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2, GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.~this group will receive also pranayama session (applied daily, one hour approximately, for six weeks) composed from (alternate nostril pranayama, diaphragmatic pranayama, rapid abdominal pranayama, Bhramari pranayama ).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupoint stimulation by laser
Description: This group will receive 2-session per-week laser stimulation (for six weeks) to some selected acupoints. The stimulated bilateral acupoints will be (LI 19, LI 20, ST2, and ST4. ST6, ST7, ST17, ST36, SI18, BL2,GB14, GV24 and EXHN5). Every acupoint will be stimulated with laser power of 100 mw that will be used on a spot area of 1 cm2 for 1 minute.
Study: NCT05242757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixed-activated Killer Immune Cells
Description: Mixed-activated Killer Immune Cells Peripheral intravenous infusion therapy
Study: NCT06186713

Intervention type: OTHER
Intervention: This was an observational study, and no Intervention was given to the patients.
Description: This was an observational study, and no Intervention was given to the patients.

Intervention type: OTHER
Intervention: This was an observational study, and no Intervention was given to the patients.
Description: This was an observational study, and no Intervention was given to the patients.
Study: NCT05971862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.
Study: NCT05490836

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEG IFN α-2b; TAF
Description: TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week. treatment continuous for 48 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG IFN α-2b; TAF
Description: TAF was orally administered once a day, and PEG IFN α-2b was subcutaneously injected 135 μg or 180μg once a week for 8 weeks and followed by 4 weeks off. treatment continuous for 48 weeks.
Study: NCT05635968

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose whole brain irradiation
Description: In the experimental group (1), 20 patients receive 4cGy x 6 times, a total of 24 cGy of irradiation. In the experimental group (2), 20 patients receive 50 cGy x 6 times, a total of 300 cGy of irradiation. All experimental groups and control group visit the hospital about 1, 6, and 12 months after irradiation to evaluate efficacy and safety.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose whole brain irradiation
Description: In the experimental group (1), 20 patients receive 4cGy x 6 times, a total of 24 cGy of irradiation. In the experimental group (2), 20 patients receive 50 cGy x 6 times, a total of 300 cGy of irradiation. All experimental groups and control group visit the hospital about 1, 6, and 12 months after irradiation to evaluate efficacy and safety.

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Low-dose whole brain irradiation
Description: In the experimental group (1), 20 patients receive 4cGy x 6 times, a total of 24 cGy of irradiation. In the experimental group (2), 20 patients receive 50 cGy x 6 times, a total of 300 cGy of irradiation. All experimental groups and control group visit the hospital about 1, 6, and 12 months after irradiation to evaluate efficacy and safety.
Study: NCT05212506

Intervention type: BIOLOGICAL
Intervention: vaccinated and unvaccinated
Description: the vaccinated :Male patients who received more than 2 injections of the covid-19 vaccine;the unvaccinated :Male patients who did not receive the covid-19 vaccine
Study: NCT05916105

Intervention type: DRUG
Intervention: Ciprofloxacin Tablets
Description: Ciprofloxacin antibiotic
Study: NCT05554796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic classic stapedotomy
Description: Patients in this group will undergo classic stapedotomy starting with removal of stapes superstructure then perforation of footplate and finally insertion of the Teflon piston.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic reversal stapedotomy
Description: Patients in this group will undergo reversal stapedotomy where perforation of footplate and insertion of Teflon piston will be done at the beginning followed by removal of stapes superstructure.
Study: NCT05349526

Intervention type: OTHER
Intervention: None, pure observational study
Description: None, pure observational study

Intervention type: OTHER
Intervention: None, pure observational study
Description: None, pure observational study
Study: NCT01422148

Intervention type: DRUG
Group type: OTHER
Intervention: Amiodarone
Description: oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
Study: NCT05701098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Break Wave extracorporeal lithotripsy
Description: The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an ultrasound imaging system and a therapy probe driven by a high voltage generator. The probe will be placed on the patient's skin, the stone located via diagnostic ultrasound and up to 30 minutes of therapy will be delivered to the stone. The therapy probe accommodates coaxial alignment of an ultrasound imaging probe for treatment guidance.
Study: NCT06210477

Intervention type: DRUG
Intervention: medical treatment for lower urinary tract symptoms
Description: The clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. Thus, this study aimed to elucidate the above association.
Study: NCT05668039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation
Description: 15 one-hour sessions during 15 weeks of enhanced external counterpulsation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Enhanced external counterpulsation
Description: 15 one-hour sessions during 15 weeks of enhanced external counterpulsation.
Study: NCT04935398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The aim is to test two treatment techniques against each other to see how effective they are.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The aim is to test two treatment techniques against each other to see how effective they are.
Study: NCT05317884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Email
Study: NCT05339581

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: Neoadjuvant IMRT will be initiated at the third treatment cycle, and the dose prescription of IMRT is for planning target volume (PTV). The prescription dose to 95%PTV should be ≥50 Gy and ≤60 Gy, and been given in daily dose fractions of 2 Gy, 5 days per week. And the final prescription dose is determined according to dose constraints for organs at risk.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until \>42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until \>7 days before liver transplantation.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Participants receive PD-1 Blockade (Pembrolizumab 200mg，Sintilimab 200mg， Camrelizumab 200mg，Tislelizumab 200mg) 100-200 mg intravenously on day 1 of a regular treatment cycle until \>42 days before liver transplantation or unacceptable toxicity develops. Participants receive Lenvatinib Mesylate Capsule (Lenvima®) 8 mg orally once daily until \>7 days before liver transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab is a recombinant anti-human PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab is a humanized anti-human PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab is a recombinant anti-human PD-1 monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Mesylate Capsule
Description: Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib Mesylate Capsule
Description: Lenvatinib (Lenvima®, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor β, RET and KIT.
Study: NCT03708549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
Study: NCT05040802

Intervention type: OTHER
Intervention: Not applicable / dataset analysis
Description: Not applicable / dataset analysis

Intervention type: OTHER
Intervention: Not applicable / dataset analysis
Description: Not applicable / dataset analysis
Study: NCT06417359

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh Fixation
Description: That mesh will be fixation with three tackers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Mesh Fixation
Description: That mesh will not be fixation
Study: NCT05997862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFFS
Description: This study introduces a new way to exercise using a hip flexion feedback system (HFFS). The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. The HFFS monitors the subject's heart rate during the exercise using a standard heart rate monitor. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated by the HFFS based on real-time heart rate readings. Therefore, the HFFS can help people stay at a specific exercise intensity by controlling how high it tells them lift their knees during the exercise.
Study: NCT06023316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mGain system
Description: passive, noninvasive surface electromyography measurement device and gaming mobile application
Study: NCT05924737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivatin
Description: 40 hours of continuous awakening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep recovery
Description: sleep recovery after 40 hours of continuous awakening
Study: NCT06079944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Description: * 6RM Load will be determined after which multipulley system will be used for treatment and treatment will be divided in to two series of 8 repetition:~* 25%, 30%,35%,40%, 50% of 6RM over the period of 6 weeks~* Speed of movement will be 2 seconds for both the eccentric and concentric phases.~* To strengthen the shoulder muscles patients will perform flexion, extension, medial and lateral rotation using multipulley system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: * TENS+ Hot pack~* Pendulum exercises and stretching exercises

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: * TENS+ Hot pack~* Pendulum exercises and stretching exercises
Study: NCT05515861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Description: Using endoscopic ultrasound (EUS) to observe the diameter and blood flow of residual variceal veins after endoscopic cyanoacrylate injection for gastric varices to evaluate the embolization effect. Endoscopic cyanoacrylate injection is performed again if the diameter of variceal vein is larger than 5 mm and with blood flow signal. After the injection, the blood flow signal is confirmed disappear by endoscopic ultrasound. Patients in the EUS group required endoscopic ultrasound assessment at each stage of the follow-up period.
Study: NCT05893602

Intervention type: OTHER
Intervention: Blood sample analysis
Description: Blood sample analysis on Cobalt and Chrome will be performed during the period under study.

Intervention type: OTHER
Intervention: Blood sample analysis
Description: Blood sample analysis on Cobalt and Chrome will be performed during the period under study.
Study: NCT04903925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impacted tooth extraction
Description: All patients will undergo a surgical tooth extraction

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Impacted tooth extraction
Description: All patients will undergo a surgical tooth extraction